CTIS | Posters & Presentations

Genentech, South San Francisco, CA, USA | 15th October 08:30am - 5:30pm PST

We’re excited to announce that our team will be attending the 2nd Annual Clinical Trial Innovation Summit 2025

This years Clinical Trial Innovation Summit brings together global leaders driving the future of clinical research and we’re proud to be part of the conversation.

We’ll be presenting on “The Importance of Cognitive Assessment in Drug Development,” exploring how innovative cognitive tools are transforming safety and efficacy evaluation across both CNS and non-CNS indications. From early-phase dose selection to long-term outcomes, sensitive computerised assessments and speech biomarkers are providing powerful new insights into drug effects.

It’s a fantastic opportunity to exchange ideas, share our perspective, and collaborate with researchers, industry leaders, and regulatory experts shaping the next generation of clinical trials.

Join us as we highlight how advances in cognitive assessment are opening new possibilities for pharmacodynamic insights, real-world data collection, and smarter trial design.

The Importance of Cognitive Assessment in Drug Development. First Author: Kenton Zavitz PhD

Presentation: Wednesday, October 15th 2025 – 9:45–10:05am

In this presentation, we’ll explore how incorporating cognitive assessment into drug development can strengthen safety and efficacy profiles for both CNS and non-CNS indications. From Phase 1 through Phase 4, computerized cognitive assessments provide valuable insight into pharmacodynamic properties, dose selection, drug interactions, short- and long-term safety, and competitive differentiation.

We’ll also highlight new developments in cognitive assessment technology, including speech and language biomarkers through voice analysis, which allow for remote, frequent, and real-world data collection.

The session will cover:

How cognitive assessments enhance understanding of pharmacodynamic properties and dosing decisions.
The role of cognitive testing in monitoring short- and long-term safety and efficacy.
The promise of speech and language biomarkers for real-world, decentralized trials.

Join us on Wednesday, October 15 at 9:45am to discover how advances in cognitive assessment are shaping the future of clinical trials and drug development.

Want to book a meeting to speak with us at the event?

Please note this calendar timezone is based in the same as the event times (UTC: – 07:00 Pacific Time), please ensure you change the timezone before booking a meeting slot.